Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat with Flu/Clo/Bu Conditioning for Allo-HSCT in Acute Leukemia
NCT02083250Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2014
- Primary completion
- Nov 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vorinostat in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 30 days. Started Mar 2014; status: completed.
02
Drugs
vorinostat
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02083250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02083250.